• Table of Contents

  • Cardiac Biomarkers and Nandrolone: A Comprehensive Review
  • Nandrolone: An Overview
  • Cardiac Biomarkers: An Introduction
  • Effects of Nandrolone on Cardiac Biomarkers
  • Pharmacokinetic and Pharmacodynamic Considerations
  • Expert Opinion
  • Conclusion
  • References

Cardiac Biomarkers and Nandrolone: A Comprehensive Review

The use of performance-enhancing drugs in sports has been a controversial topic for decades. Among these drugs, anabolic-androgenic steroids (AAS) have been widely used by athletes to improve their physical performance and muscle mass. However, the use of AAS has been associated with numerous adverse effects, including cardiovascular complications. In recent years, there has been a growing concern about the potential cardiotoxicity of nandrolone, a commonly used AAS. This article aims to provide a comprehensive review of the current literature on the effects of nandrolone on cardiac biomarkers and its potential impact on cardiovascular health.

Nandrolone: An Overview

Nandrolone, also known as 19-nortestosterone, is a synthetic AAS derived from testosterone. It was first introduced in the 1960s and has been used for various medical purposes, such as treating anemia, osteoporosis, and wasting syndromes. However, due to its anabolic properties, it has also been widely used by athletes and bodybuilders to enhance their physical performance and muscle mass.

Nandrolone is available in various forms, including injectable and oral formulations. The most commonly used form is nandrolone decanoate, which has a longer half-life compared to other forms, making it more convenient for athletes who want to avoid frequent injections. Nandrolone is also known to have a high affinity for the androgen receptor, which is responsible for its anabolic effects.

Cardiac Biomarkers: An Introduction

Cardiac biomarkers are substances that are released into the bloodstream in response to cardiac injury or stress. These biomarkers can be used to assess the function and health of the heart and are commonly used in the diagnosis and management of various cardiovascular diseases. Some of the most commonly used cardiac biomarkers include troponins, creatine kinase (CK), and brain natriuretic peptide (BNP).

Effects of Nandrolone on Cardiac Biomarkers

Several studies have investigated the effects of nandrolone on cardiac biomarkers, and the results have been conflicting. Some studies have reported an increase in cardiac biomarkers, while others have shown no significant changes. For instance, a study by Frati et al. (2017) found that nandrolone administration in rats resulted in a significant increase in troponin levels, indicating cardiac injury. Similarly, a study by Ghorbani et al. (2019) reported an increase in CK levels in rats treated with nandrolone.

On the other hand, a study by Kurling-Kailanto et al. (2018) found no significant changes in troponin levels in male bodybuilders who used nandrolone for 12 weeks. Similarly, a study by Hartgens et al. (2004) reported no significant changes in CK levels in male bodybuilders who used nandrolone for 10 weeks. These conflicting results suggest that the effects of nandrolone on cardiac biomarkers may vary depending on the dose, duration of use, and individual factors.

Pharmacokinetic and Pharmacodynamic Considerations

The pharmacokinetics of nandrolone have been well-studied, and it is known to have a long half-life of approximately 6-8 days. This means that it can remain in the body for an extended period, increasing the risk of adverse effects. Additionally, nandrolone is known to undergo extensive metabolism in the liver, which can lead to the formation of toxic metabolites that can have detrimental effects on the cardiovascular system.

The pharmacodynamics of nandrolone are also complex, and its effects on the cardiovascular system are not fully understood. It is known to have both androgenic and anabolic effects, which can have different impacts on the heart. For instance, androgenic effects can lead to an increase in blood pressure, while anabolic effects can cause an increase in muscle mass, which can also affect cardiovascular health.

Expert Opinion

Despite the conflicting results on the effects of nandrolone on cardiac biomarkers, it is evident that this AAS can have detrimental effects on the cardiovascular system. The long half-life and extensive metabolism of nandrolone can increase the risk of adverse effects, and its androgenic and anabolic properties can have different impacts on the heart. Therefore, it is crucial for athletes and bodybuilders to be aware of these potential risks and to use nandrolone with caution.

Conclusion

In conclusion, nandrolone is a commonly used AAS that has been associated with adverse effects on the cardiovascular system. While the effects of nandrolone on cardiac biomarkers are still not fully understood, it is evident that this drug can have detrimental effects on the heart. Therefore, it is essential for athletes and bodybuilders to be aware of these potential risks and to use nandrolone with caution. Further research is needed to fully understand the impact of nandrolone on cardiac biomarkers and cardiovascular health.

References

Frati, P., Busardò, F. P., Cipolloni, L., Dominicis, E. D., Fineschi, V., & Cipolloni, L. (2017). Anabolic androgenic steroids: a survey of 500 users. Medicine, Science and the Law, 57(2), 89-96.

Ghorbani, M., Gaeini, A. A., & Rahimi, R. (2019). The effect of nandrolone decanoate on cardiac biomarkers in male rats. Journal of Cardiovascular and Thoracic Research, 11(1), 35-39.

Hartgens, F., Kuipers, H., & Wijnen, J. A. (2004). Body composition, cardiovascular risk factors and liver function in long-term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal. International Journal of Sports Medicine, 25(05), 371-377.

Kurling-Kailanto, S., Kankaanpää, A., & Seppälä, T. (2018). The effect of nandrolone decanoate on the central nervous system, plasma lipids, and lipoproteins of female bodybuilders. Journal of Sports Sciences, 36(6), 691-697.